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EDITORIAL
Human African Trypanosomiasis: A Neglected Disease 
   Human African Trypanosomiasis (HAT) 
or ‘Sleeping Sickness’ is a zoonotic disease 
endemic to 36 Sub-Saharan, African Countries. 
It is caused by infection due to Trypanosoma 
brucei rhodesiense and is spread by Glossina, 
the tsetse fly. 
 
   Sleeping sickness causing Trypanosoma 
spp are haemolymphatic flagellates that 
secondarily invade the central nervous system 
(CNS). It is therefore characterized by recurrent 
fever and CNS manifestations. Major changes 
in the immune system occur during the cause 
of infection that results in lymphadenopathy, 
splenomegaly, hypergammaglobulinemia and 
hepatomegaly. 
  However, immune mechanisms cannot 
eliminate all parasites due to parasite surface 
antigen variation (variant surface antigen) 
and soluble factors actively on the synthesis 
of immune factors. They also disrupt normal 
antigen stimulated T cells activation and 
proliferation as well as cytokine chemokine 
production by lymphocytes and macrophages. 
 
        The pathophysiology of the CNS 
disease remains obscure. Presentation is also 
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widely varied from change in sleep patter (sleep/
wake cycle becomes reversed); neuropsychiatric 
manifestations such as hallucinations delirium, 
anxiety, emotional lability, attention deficit, 
aggression mania, confusion. Others include 
motor: weakness, abnormal muscle tone, gait 
disturbance, tremor, speech disturbance, sensory 
and neurologic signs and symptoms. Sometimes 
patients may present with endocrine abnormalities 
such as adrenal deficiency, thyroid dysfunction and 
hypogonodism. Cardiac involvement (myocardity) 
can occur in more severe cases. 
     Drug treatment from African Trypanosomiasis 
is possible but test is not test for cure. Drug 
treatment depends on disease stage. Pentamidine, 
Suramin and Fexinidazole are used for stage 1 
and Melarsoprol and Nifurtimox- Eflornithine 
combination reserved for stage 2 (CNS disease). 
    There is no test for cure after treatment and 
patients must be followed up for about 24 months 
for possible disease recurrence. 
      The current medicines have significant adverse 
reactions and should be given under supervision. 
More effective, less toxic, medications are urgently 
needed for treatment of HAT. Studies are also 
needed to determine mechanisms of disease in 
stage 2 and endocrine organ involvement. More 
effective parasite control methods are also urgently 
needed.
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